Contents

Volume 77 Issue 1 | ARD January 2018

Editorial

1 Learning the hard way: clinical trials in juvenile idiopathic arthritis
R A Berard, R M Laxer

Recommendation

3 Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

Viewpoint

18 Back to the future: forgetfulượng and focus on clinical assessment in rheumatoid arthritis management
R Caproni, J S Smolen

Clinical and epidemiological research

21 Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

30 The EuroMyositis registry: an international collaborative tool to facilitate myositis research

48 Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis

55 Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial

63 TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
C Mora, S Schmer, X Barakalos, M de Hooge, R Micheli, P Eer, R O Kissling, G Tantanovini, L M Wilki, M J Nissen, P Zufferey, J Berhard, U Weber, R B L Landew, D van der Heijde, A Ciereu, on behalf of the Rheumatologists of the Swiss Clinical Quality Management Program

70 The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUD): data from a prospective study
V Schönau, K Vegöl, M Englbrecht, J Wacker, D Schmid, B Manger, T Kver, G Schett

48 Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis

55 Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial

63 TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
C Mora, S Schmer, X Barakalos, M de Hooge, R Micheli, P Eer, R O Kissling, G Tantanovini, L M Wilki, M J Nissen, P Zufferey, J Berhard, U Weber, R B L Landew, D van der Heijde, A Ciereu, on behalf of the Rheumatologists of the Swiss Clinical Quality Management Program

70 The value of 18F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUD): data from a prospective study
V Schönau, K Vegöl, M Englbrecht, J Wacker, D Schmid, B Manger, T Kver, G Schett

Readers are advised to verify any information they choose to rely on.

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owner's grant editorial freedom to the Editor of ARD. ARD follows editorial guidelines on editorial independence produced by the World Association of Medical Editors and the code on good-publication-practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions. The BMJ Publishing Group, the European League Against Rheumatism or the ERA are not liable to screen, specify or determine by law. Acceptance of advertising does not imply endorsement.

The last extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group. Published by BMJ Publishing Group Ltd and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.
Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis


Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?

M Holmqvist, L Ljung, J Askling

Effect of bisphosphonates on knee replacement surgery

T Neogi, S Li, C Peloquin, D Misra, Y Zhang

Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis

C Rempenault, B Combe, T Barnetche, C Gaujoux-Viala, C Lukas, J Morel, C Hua

Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission

M Zen, L Iaccarino, M Gatto, F Saccon, M Larosa, A Ghirardello, L Punzi, A Doria

Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study


Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study


Correction

Correction: Anti-TNF treatment blocks the induction of T cell-dependent humoral responses

Electronic pages

Correspondence

e1 The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort

Z Ez-Zaitouni, M van Lunteren, P A C Bakker, R van den Berg, M Reijnierse, K M Fagerli, R B M Landewé, R Ramonda, L T H Jacobsson, F A van Gaalen, L R Lard, M C Van den Heijde

e2 Is optimising gout treatment the key to closing the mortality gap in gout patients?

R M ten Brinck, E C de Moel, J A van der Pol, S van Beest, A de Koning, T W J Huizinga

e3 Response to: ‘Is optimizing gout treatment the key to closing the mortality gap in gout patients?’ by Brinck et al

M C Fisher, S K Rai, N Lu, Y Zhang, H K Choi

e4 Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate

J M Kremer, M E Weinblatt

e5 Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt

J H Humphreys, R Costello, S M M Verstappen, W G Dixon